Compare Johnson & Johnson (JNJ) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Trade Desk Inc — how do they compare? Johnson & Johnson trades at $261.41 (market cap $618.09B), while Trade Desk Inc trades at $12.1 (market cap $5.83B). The key difference: Johnson & Johnson is far larger — about 106× Trade Desk Inc's market cap, and Johnson & Johnson pays a 2.09% dividend while Trade Desk Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Trade Desk Inc for 72 Days on average.
| JNJ | TTD | |
|---|---|---|
Market Cap | $618.09B | $5.83B |
Volume | 6,050,983 | 15,864,392 |
Sector | Health | Media |
52-Week High | $278.43 | $54.13 |
52-Week Low | $186.00 | $11.92 |
Typical Hold Time | 129 Days | 72 Days |
Enterprise Value | $646.37B | $4.78B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.44, up 1.16% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend payments. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with a $286.53 consensus target.
JNJ offers stable growth potential with diversified healthcare operations and robust profitability. Key risks include patent expirations, competitive pressures, and debt levels. Analyst consensus leans bullish with 52.5% buy ratings, though technical indicators suggest near-term caution. The stock presents a balanced opportunity for long-term investors seeking healthcare exposure.
The Trade Desk (TTD) trades at $12.08, down 0.08% with a bearish technical signal. The company shows strong fundamentals with 2025 revenue of $2.90B and net income of $443.30M, though 2026 guidance indicates slowing growth. Valuation metrics appear attractive with P/E of 0.15 and P/S of 0.02. Recent news highlights competitive pressures from Amazon and Alphabet while the company navigates workforce reductions.
Investment outlook remains cautious despite attractive valuations. The stock faces headwinds from slowing revenue growth and intense competition, but maintains leadership in programmatic advertising. Analyst consensus suggests 22% upside to $14.72 target, though mixed ratings reflect uncertainty about near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
